Polpharma Biologics has signed a major licensing agreement with Brazil’s Libbs Farmacêutica. The goal is simple and ambitious: introduce a next-generation biosimilar for autoimmune diseases to one of the world’s fastest-growing pharmaceutical markets.
Under the agreement, Polpharma Biologics will handle all development and manufacturing.
Libbs will take full responsibility for commercialization, marketing, and distribution across Brazil.
This collaboration marks a meaningful expansion for both companies and strengthens Brazil’s access to innovative biologic treatments.
With autoimmune diseases rising across Brazil, the partnership offers several advantages:
Anjan Selz, CEO of Polpharma Biologics, emphasized the significance of this market entry.
He highlighted the company’s mission to make high-quality biologics accessible worldwide and praised Libbs’ deep Brazilian market knowledge.
Libbs CEO Alcebíades de Mendonça Athayde Junior noted that the company already serves more than 15 million patients. He stated that the partnership aligns with their strategy of expanding healthcare access through a broad, high-impact portfolio.
The therapy is still in development. Polpharma Biologics expects to submit the biosimilar to Anvisa within the next three years.
Once approved, the treatment will offer an effective and well-tolerated option for people living with autoimmune conditions—an area with substantial unmet medical needs.
A global biopharmaceutical group focused on biosimilars and innovative biologics.
Its Swiss-based unit oversees the entire value cycle, from product selection to commercial strategy.
A fully Brazilian pharmaceutical company dedicated to turning scientific knowledge into health solutions.
The company invests heavily in research, innovation, and continuous improvement to deliver high-quality medicines.
This partnership blends international biotech expertise with strong local market leadership.
If approved, the upcoming biosimilar could transform access to autoimmune disease treatment in Brazil and significantly broaden therapeutic options for patients in need.